MTOR and polyhydramnios, megalencephaly, and symptomatic epilepsy: Recent advances in genomics have identified genetic mutations in regulators of the mTOR pathway as a common molecular etiology for TSC, FCDII, HME, and PMSE, thus emphasizing a central role for mTOR in the pathogenesis of these disorders (Marsan and Baulac, 2018; Muhlebner et al., 2019).